Literature DB >> 12142863

Efficacy of Adderall for Attention-Deficit/Hyperactivity Disorder: a meta-analysis.

S V Faraone1, J Biederman.   

Abstract

Stimulant medication has, for many years, been the pharmacological treatment of choice for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Several studies have shown Adderall , to be efficacious for measures of inattention, hyperactivity-impulsivity, aggression, disruptive behavior, and academic productivity. Although these studies provide useful information for clinicians treating ADHD children and adults, the variability in efficacy among the different types of measures used within each study has not been comprehensively examined. Thus, to provide a clearer picture of what conclusions can be drawn from these studies, we performed a meta-analysis. Data from the six available studies of standard release Adderall show it to be efficacious for symptoms of inattention, hyperactivity-impulsivity, and aggression, as well as global ratings. Its efficacy was significant for clinician, parent, and teacher ratings, and for both fixed- and best-dose designs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142863     DOI: 10.1177/108705470200600203

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  15 in total

1.  Some effects of stimulant medication on response allocation: a double-blind analysis.

Authors:  Michael E Kelley; Wayne W Fisher; Joanna E Lomas; Roy Q Sanders
Journal:  J Appl Behav Anal       Date:  2006

Review 2.  Attention deficit disorder in adults. Management in primary care.

Authors:  Nick Kates
Journal:  Can Fam Physician       Date:  2005-01       Impact factor: 3.275

3.  Alleviation of ADHD symptoms by non-invasive right prefrontal stimulation is correlated with EEG activity.

Authors:  Uri Alyagon; Hamutal Shahar; Aviad Hadar; Noam Barnea-Ygael; Avi Lazarovits; Hadar Shalev; Abraham Zangen
Journal:  Neuroimage Clin       Date:  2020-02-06       Impact factor: 4.881

4.  Correspondence of parent and teacher reports in medication trials.

Authors:  Stephen V Faraone; Joseph Biederman; Brenda Zimmerman
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-02       Impact factor: 4.785

Review 5.  The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder.

Authors:  Stephen V Faraone
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-02       Impact factor: 4.785

Review 6.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.

Authors:  Stephen V Faraone; Jan Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-09-10       Impact factor: 4.785

8.  Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Authors:  Josep Antoni Ramos-Quiroga; Rosa Bosch; Xavier Castells; Sergi Valero; Mariana Nogueira; Nuria Gómez; Silvia Yelmo; Marc Ferrer; Yolanda Martínez; Miguel Casas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Psychostimulants and cognition: a continuum of behavioral and cognitive activation.

Authors:  Suzanne Wood; Jennifer R Sage; Tristan Shuman; Stephan G Anagnostaras
Journal:  Pharmacol Rev       Date:  2013-12-16       Impact factor: 25.468

10.  Antisaccade-related brain activation in children with attention-deficit/hyperactivity disorder--A pilot study.

Authors:  Nicolette F Schwarz; Cynthia E Krafft; Lingxi Chi; Abby L Weinberger; David J Schaeffer; Jordan E Pierce; Amanda L Rodrigue; Celestine F Williams; Caroline H DiBattisto; Bernard L Maria; Catherine L Davis; Jennifer E McDowell
Journal:  Psychiatry Res       Date:  2015-10-03       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.